p-(t-butoxycarbonylmethoxy)-phenylacetonitrile | 124499-21-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: p-(t-butoxycarbonylmethoxy)-phenylacetonitrile
• 英文别名: tert-Butyl 2-[4-(cyanomethyl)phenoxy]acetate
• CAS: 124499-21-4
• 化学式: C₁₄H₁₇NO₃
• 分子量: 247.294
• InChiKey: AJEWOLARWFGZSH-UHFFFAOYSA-N

物化性质

• 沸点：
  366.6±22.0 °C(Predicted)
• 密度：
  1.095±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  59.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2926909090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: tert-Butyl 2-[4-(cyanomethyl)phenoxy]acetate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: tert-Butyl 2-[4-(cyanomethyl)phenoxy]acetate
CAS number: 124499-21-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H17NO3
Molecular weight: 247.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  p-(t-butoxycarbonylmethoxy)-phenylacetonitrile 在 盐酸 、 palladium 10% on activated carbon 、 氢气 作用下， 以 水 、 异丙醇 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 6.0h， 生成 [4-(2-氨基乙基)苯氧基]乙酸叔丁酯
  参考文献：
  名称：

  Fc-小分子缀合物可靶向抑制腺苷2A受体。

  摘要：

  越大越好：通过半合成方法，开发了一种Fc-小分子偶联物Fc-ZM，用于靶向抑制腺苷2A受体（A 2A R）。与单独的ZM相比，Fc–ZM表现出优越的药理特性，并且能够与分别存在于淋巴细胞和抗原呈递细胞上的A 2A R和Fc受体发生功能性相互作用。

  DOI：

  10.1002/cbic.201600337
• 作为产物：
  描述：

  溴乙酸叔丁酯 、 对羟基苯乙腈 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以81%的产率得到p-(t-butoxycarbonylmethoxy)-phenylacetonitrile
  参考文献：
  名称：

  Fc-小分子缀合物可靶向抑制腺苷2A受体。

  摘要：

  越大越好：通过半合成方法，开发了一种Fc-小分子偶联物Fc-ZM，用于靶向抑制腺苷2A受体（A 2A R）。与单独的ZM相比，Fc–ZM表现出优越的药理特性，并且能够与分别存在于淋巴细胞和抗原呈递细胞上的A 2A R和Fc受体发生功能性相互作用。

  DOI：

  10.1002/cbic.201600337

文献信息

• 2-(substituted amino) adenosines as antihypertensives
  申请人：Ciba-Geigy Corporation

  公开号：US05034381A1

  公开（公告）日：1991-07-23

  Disclosed are 2-substituted adenosine derivatives of the formula ##STR1## in which R represents a substituted amino grouping of the formula ##STR2## as defined herein; pharmaceutically acceptable ester derivatives thereof in which free hydroxy groups are esterified in the form of a pharmaceutically acceptable prodrug ester; and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; methods for their preparation; and their use in mammals as therapeutically effective adenosine-2 (A-2) agonists.

  本文披露了公式##STR1##中的2-取代腺苷衍生物，其中R代表定义如下的取代氨基团##STR2##；其药学上可接受的酯衍生物，其中游离羟基以药学上可接受的前药酯的形式酯化；以及其药学上可接受的盐；包括所述化合物的药物组合物；其制备方法；及其在哺乳动物中作为治疗有效的腺苷-2（A-2）激动剂的用途。
• 2-substituted adenosine 5'-carboxamides as antihypertensive agents
  申请人：Ciba-Geigy Corporation

  公开号：US04968697A1

  公开（公告）日：1990-11-06

  The compounds of the formula I ##STR1## wherein R represents hydrogen or lower alkyl; R.sub.1 represents C.sub.3 -C.sub.6 -cycloalkyl optionally substituted by lower alkyl, C.sub.3 -C.sub.6 -cycloalkyl-lower alkyl optionally substituted by lower alkyl, bicycloalkyl, bicycloalkyl-lower alkyl, aryl, aryl-lower alkyl, aryl-C.sub.3 -C.sub.6 -cycloalkyl, 9-fluorenyl, diaryl-lower alkyl, 9-fluorenyl-lower alkyl, cycloalkenyl-lower alkyl, bicycloalkenyl-lower alkyl, tetrahydropyranyl-lower alkyl, tetrahydrothiopyranyl-lower alkyl or adamantyl-lower alkyl; or R.sub.1 represents a bicyclic benzo-fused 5- or 6-membered saturated carbocyclic radical or a benzo-fused 5- or 6-membered saturated heterocyclic radical containing a heteroatom selected from oxygen and sulfur which is directly attached to the fused benzene ring, any said bicyclic radical being unsubstituted or substituted on the benzo portion by lower alkyl, lower alkoxy, hydroxy, halogen or trifluoromethyl, or by a substituent -W-Z in which W represents a direct bond, lower alkylene, lower alkenylene, thio-lower alkylene or oxy-lower alkylene and Z represents cyano, carboxy or carboxy derivatized in the form of a pharmaceutically acceptable ester or amide, or R.sub.1 represents any said bicyclic radical substituted-lower alkyl; or R.sub.1 represents aryl-hydroxy-lower alkyl; R.sub.2 represents hydrogen, lower alkyl or aryl-lower alkyl; R.sub.3 represents hydrogen or hydroxy; R.sub.4 represents hydrogen, lower alkyl, aryl-lower alkyl, C.sub.3 -C.sub.6 -cycloalkyl or hydroxy-lower alkyl; aryl represents an optionally substituted carbocyclic aromatic radical, being preferably 1- or 2-naphthyl, phenyl, or naphthyl or phenyl substituted by one to three of lower alkyl, lower alkoxy, hydroxy, halogen or trifluoromethyl, or naphthyl or phenyl substituted by a substitutent -W-Z in which W represents a direct bond, lower alkylene, lower alkenylene, thio-lower alkylene or oxy-lower alkylene and Z represents cyano, carboxy or carboxy derivatized in the form of a pharmaceutically acceptable ester or amide; or aryl represents a heterocyclic aromatic radical, being preferably pyridyl or thienyl, each optionally substituted as described above for phenyl; pharmaceutically acceptable ester derivatives thereof in which free hydroxy groups are esterified in the form of a pharmaceutically acceptable ester; and pharmaceutically acceptable salts thereof; their preparation; and their use as adenosine-2 receptor agonists are disclosed.

  公式I的化合物如下：其中R代表氢或低碳基；R1代表C3-C6-环烷基，可选地被低碳基取代，C3-C6-环烷基-低碳基，可选地被低碳基取代，双环烷基，双环烷基-低碳基，芳基，芳基-低碳基，芳基-C3-C6-环烷基，9-芴基，双芳基-低碳基，9-芴基-低碳基，环烯基-低碳基，双环烯基-低碳基，四氢吡喃基-低碳基，四氢硫吡喃基-低碳基或金刚烷基-低碳基；或R1代表一个双环苯并5-或6-成员饱和碳环基或一个苯并5-或6-成员饱和杂环基，其中所述的杂原子从氧和硫中选择，直接连接到融合的苯环上，任何所述的双环基在苯基部分上未取代或被低碳基，低烷氧基，羟基，卤素或三氟甲基取代，或被取代基-W-Z取代，其中W代表直接键，低碳基，低烯基，硫代低碳基或氧代低碳基，Z代表氰基，羧基或以药学上可接受的酯或酰胺形式衍生的羧基；或R1代表任何所述的双环基取代的低碳基；或R1代表芳基-羟基-低碳基；R2代表氢，低碳基或芳基-低碳基；R3代表氢或羟基；R4代表氢，低碳基，芳基-低碳基，C3-C6-环烷基或羟基-低碳基；芳基代表选择性取代的碳环芳基基团，最好是1-或2-萘基，苯基，或被1到3个低碳基，低烷氧基，羟基，卤素或三氟甲基取代的萘基或苯基，或萘基或苯基被取代基-W-Z取代，其中W代表直接键，低碳基，低烯基，硫代低碳基或氧代低碳基，Z代表氰基，羧基或以药学上可接受的酯或酰胺形式衍生的羧基；或芳基代表选择性取代的杂环芳基基团，最好是吡啶基或噻吩基，每个基团可选择性地被上述描述的基团取代；其药学上可接受的酯衍生物，其中游离的羟基被酯化为药学上可接受的酯；以及其药学上可接受的盐；其制备方法；以及其作为腺苷-2受体激动剂的用途。
• Diagnostic uses of 2-substituted adenosine carboxamides
  申请人：King Pharmaceuticals Research and Development, Inc.

  公开号：US06368573B1

  公开（公告）日：2002-04-09

  The present invention discloses a method for measuring myocardial function in a mammal in need of such measurement by: a) administering 2-substituted adenosine carboxamide derivatives at a dosage rate of less than 1 &mgr;g/kg/min, preferably between about 0.01 and 1 &mgr;g/kg/min; and then: b) performing a technique on the mammal to detect myocardial function. The method can be used to diagnose myocardial dysfunction by electrophysiologic analysis or by imaging the vasculature of the heart, especially under conditions that simulate stress.

  本发明公开了一种测量需要进行心肌功能测量的哺乳动物的方法，包括：a)以小于1 &mgr;g/kg/min的剂量率给予2-取代腺苷酸甲酰衍生物，最好在大约0.01和1 &mgr;g/kg/min之间；然后：b)对哺乳动物进行技术操作以检测心肌功能。该方法可用于通过电生理分析或通过成像心脏血管特别是在模拟应激条件下来诊断心肌功能异常。
• Certain adenosine 5'-carboxamide derivatives
  申请人：CIBA-GEIGY AG

  公开号：EP0277917A2

  公开（公告）日：1988-08-10

  The compounds of the formula I wherein R represents hydrogen or lower alkyl; R¹ represents cyclo­alkyl, cycloalkyl-lower alkyl, 2-norbornanyl, 2-norbornanyl-lower alkyl, aryl, aryl-lower alkyl, aryl-cycloalkyl, 9-fluorenyl, diaryl-lower alkyl or 9-fluorenyl-lower alkyl; or R¹ represents a bicyclic benzo-fused 5- or 6-membered saturated carbocyclic radical or a benzo-fused 5- or 6-membered saturated heterocyclic radical containing a heteroatom selected from oxygen and sulfur which is directly attached to the fused benzene ring, any said bicyclic radical being unsubstituted or substituted on the benzo portion by lower alkyl, lower alkoxy, hydroxy, halogen or trifluoromethyl, or by a substituent -W-Z in which W represents a direct bond, lower alkylene, lower alkenylene, thio-lower alkylene or oxy-lowe alkylene and Z represents cyano, carboxy or carboxy derivatized in the form of a pharmaceutically acceptable ester or amide; R² represents hydrogen, lower alkyl or aryl-lower alkyl; R³ represents hydrogen or hydroxy; R⁴ represents hydrogen, lower alkyl, aryl-lower alkyl, cycloalkyl or hydroxy-lower alkyl; pharmaceutically accept­able ester derivatives thereof in which free hydroxy groups are esterified in form of a pharmaceutically acceptable ester; pharmaceutically acceptable salts thereof; their preparation, and their use as adenosine-2 receptor agonists are disclosed.

  式 I 的化合物 其中 R 代表氢或低级烷基；R¹ 代表环烷基、环烷基-低级烷基、2-降冰片烷基、2-降冰片烷基-低级烷基、芳基、芳基-低级烷基、芳基-环烷基、9-芴基、二芳基-低级烷基或 9-芴基-低级烷基；或 R¹ 代表双环苯并融合的 5 或 6 元饱和碳环基，或苯并融合的 5 或 6 元饱和杂环基，其中含有直接连接到融合苯环上的选自氧和硫的杂原子，任何上述双环基均未被取代或在苯并部分被低级烷基取代、低级烷氧基、羟基、卤素或三氟甲基，或取代基-W-Z，其中 W 代表直接键、低级亚烷基、低级亚烯基、硫代低级亚烷基或氧代低级亚烷基，Z 代表氰基、羧基或以药学上可接受的酯或酰胺形式衍生的羧基；R²代表氢、低级烷基或芳基-低级烷基；R³代表氢或羟基；R⁴代表氢、低级烷基、芳基-低级烷基、环烷基或羟基-低级烷基；公开了其药学上可接受的酯衍生物，其中游离羟基以药学上可接受的酯的形式酯化；其药学上可接受的盐；其制备及其作为腺苷-2 受体激动剂的用途。
• Certain 2-substituted adenosine derivatives
  申请人：CIBA-GEIGY AG

  公开号：EP0323807A2

  公开（公告）日：1989-07-12

  Disclosed are 2-substituted adenosine derivatives of the formula wherein R represents a substituted amino grouping as defined in the specification, which are therapeutically effective adenosine-2 (A-2) agonists. They are prepared by methods known per se.

  公开了式中的 2-取代腺苷衍生物 其中 R 代表说明书中定义的取代氨基，是治疗有效的腺苷-2（A-2）激动剂。它们是通过本身已知的方法制备的。